Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.58 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 2/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30537979 | 1.00 | SIGMAR1 (0.58) | SIGMAR1OPRK1TSHRMAOBMAOA | |
| SCHEMBL15272040 | 0.87 | SIGMAR1 (0.62) | SIGMAR1OPRK1TSHRMAOBMAOA | |
| SCHEMBL3428040 | 0.85 | SIGMAR1 (0.54) | SIGMAR1OPRK1TSHRCYP2C19CYP1A2 | |
| SCHEMBL9217552 | 0.81 | SIGMAR1 (0.60) | SIGMAR1OPRK1TSHRMAOBMAOA | |
| SCHEMBL5461014 | 0.81 | SIGMAR1 (0.56) | SIGMAR1OPRK1TSHRPYCR1CYP2D6 | |
| SCHEMBL1058423 | 0.80 | CTBP2 (0.50) | SIGMAR1MAOBACHEALDH1A1NPC1 | |
| SCHEMBL6863601 | 0.79 | ALDH1A1 (0.59) | SIGMAR1ALDH1A1SMN1; SMN2MAPTLMNA | |
| SCHEMBL1515860 | 0.79 | LMNA (0.43) | SIGMAR1TSHRSMN1; SMN2LMNAHTT | |
| SCHEMBL520733 | 0.79 | MEN1 (0.58) | TSHRMAOBMAOACYP2D6CYP2C9 | |
| SCHEMBL9568285 | 0.79 | SIGMAR1 (0.54) | SIGMAR1OPRK1TSHRPYCR1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240352122-A1 | ANTI-CD48 ANTIBODIES, ANTIBODY DRUG CONJUGATES, AND USES THEREOF | NOVARTIS AG (CH) | 2024-10-24 | — | — | US | disclosed |
| US-11999786-B2 | Anti-CD48 antibodies, antibody drug conjugates, and uses thereof | NOVARTIS AG (CH) | 2024-06-04 | — | — | US | disclosed |
| EP-4251648-A2 | ANTI-CD48 ANTIBODIES, ANTIBODY DRUG CONJUGATES, AND USES THEREOF | Novartis AG (CH) | 2023-10-04 | — | — | EP | disclosed |
| CN-116615252-A | anti-CD 48 antibodies, antibody drug conjugates and uses thereof | 诺华股份有限公司 | 2023-08-18 | — | — | CN | disclosed |
| WO-2022112942-A2 | ANTI-CD48 ANTIBODIES, ANTIBODY DRUG CONJUGATES, AND USES THEREOF | NOVARTIS AG (CH) | 2022-06-02 | — | — | WO | disclosed |
| US-20220162308-A1 | ANTI-CD48 ANTIBODIES, ANTIBODY DRUG CONJUGATES, AND USES THEREOF | NOVARTIS AG (CH) | 2022-05-26 | — | — | US | disclosed |
| US-20210228731-A1 | ANTIBODY DRUG CONJUGATES FOR ABLATING HEMATOPOIETIC STEM CELLS | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. | 2021-07-29 | — | — | US | disclosed |
| EP-3810205-A2 | ANTIBODY DRUG CONJUGATES FOR ABLATING HEMATOPOIETIC STEM CELLS | Novartis AG (CH) | 2021-04-28 | — | — | EP | disclosed |
| CN-112437675-A | Antibody drug conjugates for ablating hematopoietic stem cells | 诺华股份有限公司 | 2021-03-02 | — | — | CN | disclosed |
| WO-2019244082-A2 | ANTIBODY DRUG CONJUGATES FOR ABLATING HEMATOPOIETIC STEM CELLS | NOVARTIS AG (CH) | 2019-12-26 | — | — | WO | disclosed |
| US-9283222-B2 | Inhibitors of poly(ADP-ribose)polymerase | ABBVIE INC. (US) | 2016-03-15 | — | — | US | disclosed |
| EP-2698062-B1 | Inhibitors of poly(adp-ribose)polymerase | ABBVIE INC (US) | 2015-06-24 | — | — | EP | disclosed |
| US-20140212509-A1 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | ABBVIE INC. (US) | 2014-07-31 | — | — | US | disclosed |
| EP-2698062-A1 | Inhibitors of poly(adp-ribose)polymerase | Abbvie Inc. (US) | 2014-02-19 | — | — | EP | disclosed |
| EP-2120579-B1 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | ABBVIE INC (US) | 2013-11-13 | — | — | EP | disclosed |
| US-8466150-B2 | Inhibitors of poly(ADP-ribose)polymerase | ABBOTT LABORATORIES (US) | 2013-06-18 | — | — | US | disclosed |
| EP-2120579-A1 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | ABBOTT LABORATORIES (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080269234-A1 | Such as 7-((cyclohexyl)methyl) pyrido(2,3-d )pyridazine-4(5H)-one; anticancer agents; antiinflammatory agents;antiischemic agents; antidiabetic agents | ABBOTT LABORATORIES (US) | 2008-10-30 | — | — | US | disclosed |
| WO-2008083027-A1 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | ABBOTT LABORATORIES (US) | 2008-07-10 | — | — | WO | disclosed |
| US-20080161280-A1 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11999786-B2 | Anti-CD48 antibodies, antibody drug conjugates, and uses thereof | ITGB8, ITGA8, CD4 | SIGMAR1 2559/4885OPRK1 3489/4885TSHR 2740/4885 |
| US-20080269234-A1 | Such as 7-((cyclohexyl)methyl) pyrido(2,3-d )pyridazine-4(5H)-one; anticancer agents; antiinflammatory agents;antiischemic agents; antidiabetic agents | PARP1, DPYD, PARP2 | SIGMAR1 2997/4885OPRK1 1463/4885TSHR 4199/4885 |
| US-20240352122-A1 | ANTI-CD48 ANTIBODIES, ANTIBODY DRUG CONJUGATES, AND USES THEREOF | ITGB8, ITGA8, CD4 | SIGMAR1 2559/4885OPRK1 3489/4885TSHR 2740/4885 |
| US-20140212509-A1 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | PARP1, PARP2, PARP3 | SIGMAR1 2551/4885OPRK1 1283/4885TSHR 4185/4885 |
| US-20210228731-A1 | ANTIBODY DRUG CONJUGATES FOR ABLATING HEMATOPOIETIC STEM CELLS | BCR, ABL1, CD47 | SIGMAR1 4268/4885OPRK1 3703/4885TSHR 3696/4885 |
| US-20220162308-A1 | ANTI-CD48 ANTIBODIES, ANTIBODY DRUG CONJUGATES, AND USES THEREOF | ITGB8, ITGA8, CD4 | SIGMAR1 2559/4885OPRK1 3489/4885TSHR 2740/4885 |
| US-20080161280-A1 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | PARP1, PARP2, PARP3 | SIGMAR1 2551/4885OPRK1 1283/4885TSHR 4185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.